I ke aupuni o ka lāʻau lapaʻau hou, ua hōʻike ʻia nā lāʻau antibiotic kekahi o nā holomua koʻikoʻi, me ka hoʻohaʻahaʻa haʻahaʻa i ka nui a me ka make e pili ana i nā maʻi microbial. ʻO ko lākou hiki ke hoʻololi i nā hopena lapaʻau o nā maʻi bacterial ua hoʻonui i ke ola o nā maʻi he nui. He mea koʻikoʻi nā lāʻau antibiotic i nā kaʻina hana lapaʻau paʻakikī, e like me nā ʻokiʻoki, nā hoʻokomo implant, nā transplants, a me ka chemotherapy. Eia nō naʻe, ʻo ka puka ʻana mai o nā pathogens kūʻē i ka antibiotic i mea e hopohopo nui nei, e hōʻemi ana i ka pono o kēia mau lāʻau i ka wā. Ua hoʻopaʻa ʻia nā ʻano o ka pale ʻana i nā lāʻau antibiotic ma nā ʻano āpau o nā lāʻau antibiotic i ka wā e hiki mai ana nā hoʻololi microbial. ʻO ke koʻikoʻi koho i hana ʻia e nā lāʻau antimicrobial ua kōkua i ka piʻi ʻana o nā maʻi kūpaʻa, e waiho ana i kahi paʻakikī nui i ke olakino honua.
No ka pale ʻana i ka pilikia koʻikoʻi o ka pale ʻana i ka antimicrobial, pono ia e hoʻokō i nā kulekele hoʻomalu i ka maʻi maʻi e pale ai i ka laha ʻana o nā pathogens kū'ē, me ka hōʻemi ʻana i ka hoʻohana ʻana i nā lāʻau antibiotic. Eia kekahi, aia kahi koi koi no nā ʻano lapaʻau ʻē aʻe. Ua puka mai ka Hyperbaric Oxygen Therapy (HBOT) ma ke ʻano he ʻano hoʻohiki i kēia pōʻaiapili, e pili ana i ka inhalation o 100% oxygen ma nā pae kaomi kūikawā no kekahi manawa. Hoʻonoho ʻia ma ke ʻano he lāʻau lapaʻau mua a hoʻohui ʻia paha no nā maʻi, hiki i ka HBOT ke hāʻawi i ka manaʻolana hou i ka mālama ʻana i nā maʻi koʻikoʻi i hoʻokumu ʻia e nā pathogens kū'ē i ka antibiotic.
Hoʻohana nui ʻia kēia lāʻau lapaʻau ma ke ʻano he lāʻau lapaʻau mua a ʻē aʻe paha no nā ʻano like ʻole, e like me ka mumū, carbon monoxide poisoning, nā ʻeha mau, nā maʻi ischemic, a me nā maʻi. ʻO nā noi lapaʻau o HBOT i ka mālama ʻana i nā maʻi he hohonu, e hāʻawi ana i nā pono waiwai nui i nā maʻi.
Nā noi lapaʻau o ka Hyperbaric Oxygen Therapy i ka maʻi maʻi
Ke kākoʻo ikaika nei nā hōʻike o kēia manawa i ka hoʻohana ʻana o HBOT, ma ke ʻano he hoʻomalu kūʻokoʻa a me ka hoʻohui ʻana, e hōʻike ana i nā pono nui i nā maʻi maʻi. I ka wā o ka HBOT, hiki ke piʻi i ka 2000 mmHg ke kaomi ʻana o ke koko o ka oxygen, a ʻo ka hopena kiʻekiʻe o ka oxygen-tissue pressure gradient hiki ke hoʻokiʻekiʻe i nā pae oxygen kiko i 500 mmHg. He waiwai nui ia mau hopena i ka paipai ʻana i ka ho'ōla ʻana i nā pane inflammatory a me nā microcirculatory disruptions i ʻike ʻia ma nā wahi ischemic, a me ka mālama ʻana i ka maʻi compartment.
Hiki i ka HBOT ke hoʻopili i nā kūlana hilinaʻi i ka ʻōnaehana pale. Hōʻike ka noiʻi hiki i ka HBOT ke hoʻopau i nā maʻi autoimmune a me nā pane kūlohelohe antigen-induced, e kōkua ana i ka mālama ʻana i ka graft tolerance ma o ka hoʻēmi ʻana i ke kahe o nā lymphocytes a me nā leukocytes ʻoiai e hoʻololi ana i nā pane kūlohelohe. Eia kekahi, HBOTkākoʻo hoʻōlai nā ʻili ʻili maʻamau ma o ka hoʻoulu ʻana i ka angiogenesis, kahi hana koʻikoʻi no ka hoʻomaikaʻi ʻana. Hoʻoikaika pū kēia lāʻau lapaʻau i ke kūkulu ʻana i ka collagen matrix, kahi hana koʻikoʻi i ka ho'ōla ʻana i ka ʻeha.
Pono e nānā nui ʻia i kekahi mau maʻi, ʻo ia hoʻi nā maʻi hohonu a paʻakikī hoʻi e mālama ʻia e like me ka necrotizing fasciitis, osteomyelitis, nā maʻi palupalu mau loa, a me ka endocarditis infectious. ʻO kekahi o nā noi lapaʻau maʻamau o ka HBOT no nā maʻi ʻili a me ka osteomyelitis e pili ana me nā pae oxygen haʻahaʻa i hana pinepine ʻia e ka anaerobic a i ʻole nā bacteria kū'ē.
1. Na ma'i wawae diabetic
Ka wāwae maʻi diabetesʻO nā maʻi maʻi maʻi maʻi he complication maʻamau i waena o nā maʻi diabetic, e pili ana i ka 25% o kēia heluna. Piʻi pinepine nā maʻi i loko o kēia mau maʻi ʻeha (ʻo ia ka 40% -80% o nā hihia) a alakaʻi i ka maʻi maʻi a me ka make. ʻO nā maʻi maʻi wāwae diabetic (DFIs) he mau maʻi polymicrobial me nā ʻano maʻi bacterial anaerobic i ʻike ʻia. ʻO nā mea like ʻole, me nā hemahema o ka hana fibroblast, nā pilikia hoʻokumu collagen, nā ʻōnaehana immune cellular, a me ka hana phagocyte, hiki ke pale i ka ho'ōla ʻana i nā maʻi maʻi maʻi. Ua ʻike kekahi mau haʻawina i ka oxygenation ʻili impaired ma ke ʻano he kumu koʻikoʻi koʻikoʻi no ka ʻoki ʻana e pili ana i nā DFI.
ʻO kekahi o nā koho i kēia manawa no ka mālama ʻana i ka DFI, Ua hōʻike ʻia ʻo HBOT e hoʻonui nui i nā helu ho'ōla no nā maʻi maʻi maʻi maʻi wāwae, ma hope o ka hoʻemi ʻana i ka pono o ka ʻoki ʻana a me nā hana ʻoki paʻakikī. ʻAʻole ia e hōʻemi wale i ka pono no nā kaʻina hana waiwai, e like me ka ʻoki ʻana i ka flap a me ka grafting ʻili, akā hāʻawi pū kekahi i nā kumukūʻai haʻahaʻa a me nā hopena liʻiliʻi liʻiliʻi i hoʻohālikelike ʻia i nā koho hana. He haʻawina na Chen et al. Ua hōʻike ʻia ʻoi aku ma mua o 10 mau manawa o HBOT i alakaʻi i kahi 78.3% hoʻomaikaʻi i nā helu hoʻōla ʻeha i nā maʻi maʻi maʻi.
2. ʻO nā maʻi maʻi necrotizing
ʻO nā maʻi ʻiʻo palupalu necrotizing (NSTIs) he polymicrobial, maʻamau e puka mai ana mai ka hui pū ʻana o nā maʻi bacterial aerobic a me anaerobic a pili pinepine i ka hana kinoea. ʻOiai he kakaikahi nā NSTI, hōʻike lākou i ka nui o ka make ma muli o ko lākou holomua wikiwiki. ʻO ka maʻi a me ka mālama ʻana i ka manawa kūpono a me ka mālama ʻana he kī nui i ka loaʻa ʻana o nā hopena maikaʻi, a ua ʻōlelo ʻia ʻo HBOT ma ke ʻano he ala hoʻohui no ka mālama ʻana i nā NSTI. ʻOiai ke mau nei ka hoʻopaʻapaʻa e pili ana i ka hoʻohana ʻana o HBOT i nā NSTI ma muli o ka nele o nā haʻawina i manaʻo ʻia.Hōʻike nā hōʻike e pili ana ia me ka hoʻomaikaʻi ʻana i ka nui o ke ola a me ka mālama ʻana i ke kino i nā maʻi NSTI. Ua hōʻike ʻia kahi haʻawina retrospective i ka emi nui o ka make ma waena o nā maʻi NSTI e loaʻa ana i ka HBOT.
1.3 Nā maʻi maʻi ma ka pūnaewele
Hiki ke hoʻokaʻawale ʻia nā SSI ma muli o ke kahua anatomical o ka maʻi a hiki ke ala mai nā pathogens like ʻole, me ka bacteria aerobic a me ka anaerobic. ʻOiai ka holomua ʻana o nā hana hoʻomalu maʻi, e like me nā ʻenehana sterilization, ka hoʻohana ʻana i nā lāʻau antibiotic prophylactic, a me nā hoʻomaikaʻi ʻana i nā hana ʻokiʻoki, e noho mau ana nā SSI.
Ua noiʻi kekahi loiloi koʻikoʻi i ka maikaʻi o ka HBOT i ka pale ʻana i nā SSI hohonu i ke kaʻina neuromuscular scoliosis. Hiki i ka HBOT preoperative ke hoʻemi nui i ka ulu ʻana o nā SSI a hoʻomaʻamaʻa i ka hoʻōla ʻana i ka ʻeha. Hoʻokumu kēia lāʻau lapaʻau non-invasive i kahi e hoʻokiʻekiʻe ʻia ai nā pae oxygen i loko o nā ʻiʻo ʻeha, i pili pū me ka hana pepehi oxidative e kūʻē i nā pathogens. Hoʻohui ia, e kamaʻilio ana i nā pae koko haʻahaʻa a me ka oxygen e kōkua i ka hoʻomohala ʻana o nā SSI. Ma waho aʻe o nā hoʻolālā hoʻokele maʻi ʻē aʻe, ua ʻōlelo ʻia ʻo HBOT no nā ʻoki hoʻomaʻemaʻe maʻemaʻe e like me nā kaʻina colorectal.
1.4 Puhi
ʻO ke ahi nā ʻeha i hoʻokumu ʻia e ka wela nui, ke au uila, nā kemika, a i ʻole ka radiation a hiki ke hoʻonui i ka nui o ka maʻi a me ka make. Pono ka HBOT i ka mālama ʻana i nā kuni ma o ka hoʻonui ʻana i ka pae o ka oxygen i nā ʻiʻo i hōʻino ʻia. ʻOiai ke hōʻike nei nā haʻawina holoholona a me nā lāʻau lapaʻau i nā hopena like ʻole e pili anaka hopena o ka HBOT i ka mālama ʻana i ke ahi, kahi noiʻi e pili ana i nā maʻi kuni 125 i hōʻike ʻia ʻaʻole i hōʻike ʻo HBOT i ka hopena koʻikoʻi i ka nui o ka make a i ʻole ka helu o nā ʻokiʻoki i hana ʻia akā ua hōʻemi i ka manawa hoʻōla maʻamau (19.7 mau lā i hoʻohālikelike ʻia me 43.8 mau lā). ʻO ka hoʻohui ʻana i ka HBOT me ka hoʻokele ahi holoʻokoʻa hiki ke hoʻomalu pono i ka sepsis i nā maʻi kuni, e alakaʻi ana i nā manawa hoʻōla pōkole a hōʻemi i nā koi wai. Eia nō naʻe, koi ʻia nā noiʻi ʻoi aku ka nui e hōʻoia i ke kuleana o HBOT i ka mālama ʻana i nā kuni nui.
1.5 Osteomyelitis
ʻO ka Osteomyelitis kahi maʻi o ka iwi a i ʻole ka iwi iwi i hana pinepine ʻia e nā pathogen bacteria. He mea paʻakikī ka mālama ʻana i ka osteomyelitis ma muli o ka liʻiliʻi o ke koko i nā iwi a me ka liʻiliʻi o ke komo ʻana o nā lāʻau antibiotic i loko o ka momona. Hōʻike ʻia ka osteomyelitis maʻi e nā maʻi pathogens mau loa, ʻeha ʻeha, a me ka hoʻokumu ʻana o ka iwi necrotic. ʻO ka osteomyelitis refractory e pili ana i nā maʻi iwi maʻi e hoʻomau a hoʻi hou ʻia me ka mālama pono ʻana.
Ua hōʻike ʻia ʻo HBOT e hoʻomaikaʻi maikaʻi i nā pae o ka oxygen i loko o nā ʻiʻo iwi maʻi. Hōʻike ka nui o nā hihia a me nā haʻawina cohort e hoʻomaikaʻi ʻo HBOT i nā hopena lapaʻau no nā maʻi osteomyelitis. ʻIke ʻia e hana ma o nā ʻano hana like ʻole, me ka hoʻonui ʻana i ka hana metabolic, ke kāohi ʻana i nā pathogens bacteria, hoʻonui i nā hopena antibiotic, hoʻemi i ka mumū, a me ka hoʻōla ʻana.kaʻina hana. Ma hope o ka HBOT, 60% a hiki i ka 85% o nā maʻi me ka osteomyelitis maʻi mau, hōʻike i nā hōʻailona o ka hoʻopau ʻana i ka maʻi.
1.6 Nā maʻi fungal
Ma ke ao holoʻokoʻa, ʻoi aku ma mua o ʻekolu miliona mau kānaka e loaʻa ana i nā maʻi fungal maʻi a i ʻole invasive, e alakaʻi ana i ka make ma luna o 600,000 i kēlā me kēia makahiki. Hoʻopili pinepine ʻia nā hopena lapaʻau no nā maʻi fungal ma muli o nā kumu e like me ke kūlana immune i hoʻololi ʻia, nā maʻi lalo, a me nā ʻano virulence pathogen. Ke lilo nei ʻo HBOT i koho therapeutic uʻi i nā maʻi fungal koʻikoʻi ma muli o kona palekana a me ke ʻano non-invasive. Hōʻike nā haʻawina e hiki ke hana maikaʻi ʻo HBOT i nā pathogen fungal e like me Aspergillus a me Mycobacterium tuberculosis.
Hoʻolaha ʻo HBOT i nā hopena antifungal ma ke kāohi ʻana i ka hoʻokumu ʻana o ka biofilm o Aspergillus, me ka hoʻonui ʻana i ka pono i ʻike ʻia i nā ʻano i nele i nā genes superoxide dismutase (SOD). ʻO nā kūlana hypoxic i ka wā o nā maʻi fungal e hoʻopilikia i ka lawe ʻana i ka lāʻau antifungal, e hana ana i ka piʻi ʻana o ka nui o ka oxygen mai HBOT i mea kōkua pono, ʻoiai ke koi ʻia ka noiʻi hou aku.
ʻO nā mea Antimicrobial o HBOT
ʻO ke kaiapuni hyperoxic i hana ʻia e HBOT e hoʻomaka i ka hoʻololi physiological a me ka biochemical e hoʻoulu ai i nā waiwai antibacterial, e lilo ia i mea lapaʻau adjunct maikaʻi no ka maʻi. Hōʻike ka HBOT i nā hopena kupaianaha e kūʻē i ka bacteria aerobic a me ka nui o ka bacteria anaerobic ma o nā hana e like me ka hana bactericidal pololei, hoʻonui i nā pane kūlohelohe, a me nā hopena synergistic me nā mea antimicrobial kūikawā.
2.1 Nā hopena antibacterial pololei o HBOT
ʻO ka hopena antibacterial pololei o ka HBOT ka mea nui i ka hanauna o nā ʻano oxygen reactive (ROS), e komo pū ana me nā anion superoxide, hydrogen peroxide, hydroxyl radicals, a me nā hydroxyl ions-ʻo ia mau mea a pau e ala mai i ka wā o ka cellular metabolism.
He mea nui ka pilina ma waena o O₂ a me nā ʻāpana cellular i ka hoʻomaopopo ʻana i ke ʻano o ka ROS i loko o nā cell. Ma lalo o kekahi mau kūlana i kapa ʻia ʻo ke koʻikoʻi oxidative, ua hoʻopau ʻia ke kaulike ma waena o ka hoʻokumu ʻana o ROS a me kona hoʻohaʻahaʻa ʻana, e alakaʻi ana i nā kiʻekiʻe kiʻekiʻe o ROS i nā cell. Hoʻopili ʻia ka hana ʻana o ka superoxide (O₂⁻) e ka superoxide dismutase, a laila hoʻololi i ka O₂⁻ i hydrogen peroxide (H₂O₂). Hoʻonui hou ʻia kēia hoʻololi ʻana e ka hopena Fenton, nāna e hoʻoheheʻe iā Fe²⁺ e hoʻohua i nā radical hydroxyl (·OH) a me Fe³⁺, pēlā e hoʻomaka ai i kahi kaʻina redox pōʻino o ka hoʻokumu ʻana o ROS a me ka pōʻino kelepona.
ʻO nā hopena ʻawaʻawa o ka ROS e kuhikuhi ana i nā ʻāpana kelepona koʻikoʻi e like me DNA, RNA, protein, a me nā lipids. ʻO ka mea nui, ʻo DNA ka pahuhopu nui o ka cytotoxicity i hoʻopili ʻia e H₂O₂, no ka mea e hoʻopau i nā hale deoxyribose a hōʻino i nā haku mele. ʻO ka pōʻino kino i hoʻokomo ʻia e ROS e hoʻonui i ke ʻano helix o DNA, hiki ke hopena mai ka lipid peroxidation i hoʻoiho ʻia e ROS. Hōʻike kēia i nā hopena maikaʻi ʻole o nā pae ROS kiʻekiʻe i loko o nā ʻōnaehana olaola.
Hana Antimicrobial o ROS
He kuleana koʻikoʻi ka ROS i ka pale ʻana i ka ulu ʻana o ka microbial, e like me ka mea i hōʻike ʻia ma o HBOT-induced ROS generation. ʻO nā hopena ʻawaʻawa o ka ROS e kuhikuhi pololei ana i nā mea kelepona e like me DNA, nā protein, a me nā lipids. Hiki ke hoʻopōʻino pono i nā lipids nā ʻano kiʻekiʻe o nā ʻano oxygen ikaika, e alakaʻi ana i ka lipid peroxidation. Hoʻopili kēia kaʻina hana i ka pono o nā membrane cell a, no laila, ka hana o nā mea hoʻokipa e pili ana i ka membrane a me nā protein.
Eia kekahi, ʻo nā protein, ʻo ia hoʻi nā pahuhopu molecular koʻikoʻi o ROS, e hoʻololi i nā hoʻololi oxidative kikoʻī i nā koena amino acid e like me cysteine, methionine, tyrosine, phenylalanine, a me tryptophan. No ka laʻana, ua hōʻike ʻia ʻo HBOT e hoʻohuli i nā loli oxidative i kekahi mau protein i loko o E. coli, me ka elongation factor G a me DnaK, no laila e hoʻopili ai i kā lākou hana kelepona.
Hoʻonui i ka palekana ma o HBOT
ʻO nā waiwai anti-inflammatory o HBOTua hoʻopaʻa ʻia, e hōʻike ana i ke koʻikoʻi no ka hoʻohaʻahaʻa ʻana i ka pōʻino o ke kino a me ke kāohi ʻana i ka piʻi ʻana o ka maʻi. Hoʻopilikia nui ʻo HBOT i ka hōʻike ʻana o nā cytokines a me nā mea hoʻoponopono inflammatory ʻē aʻe, e hoʻohuli ana i ka pane ʻana o ka immune. Ua nānā nā ʻōnaehana hoʻokolohua like ʻole i nā loli ʻokoʻa i ka hōʻike gene a me ka hoʻokumu ʻana o ka protein ma hope o ka HBOT, ka mea e hoʻonui a hoʻohaʻahaʻa paha i nā kumu ulu a me nā cytokines.
I ka wā o ke kaʻina hana HBOT, hoʻonui ʻia nā pae O₂ i nā ʻano pane kelepona, e like me ke kāohi ʻana i ka hoʻokuʻu ʻana o nā mea hoʻolaha pro-inflammatory a me ka hāpai ʻana i ka lymphocyte a me ka neutrophil apoptosis. ʻO ka hui pū ʻana, hoʻomaikaʻi kēia mau hana i nā hana antimicrobial o ka ʻōnaehana pale, ma laila e maʻalahi ai ka ho'ōla ʻana i nā maʻi.
Eia kekahi, hōʻike nā haʻawina e hiki ke hoʻonui i nā pae O₂ i ka wā HBOT e hōʻemi i ka hōʻike ʻana o nā cytokine pro-inflammatory, me interferon-gamma (IFN-γ), interleukin-1 (IL-1), a me interleukin-6 (IL-6). Hoʻopili pū kēia mau hoʻololi i ka hoʻohaʻahaʻa ʻana i ka ratio o CD4: CD8 T cell a me ka hoʻololi ʻana i nā mea hoʻokipa soluble ʻē aʻe, e hoʻonui ana i nā pae interleukin-10 (IL-10), he mea koʻikoʻi no ka pale ʻana i ka mumū a me ka hoʻōla ʻana.
Hoʻopili ʻia nā hana antimicrobial o HBOT me nā ʻano hana biological paʻakikī. Ua hōʻike ʻia nā superoxide a me ka piʻi kiʻekiʻe e hoʻoikaika ʻole i ka hana antibacterial HBOT-induced a me neutrophil apoptosis. Ma hope o ka HBOT, hoʻonui ʻia kahi kiʻekiʻe i ka pae o ka oxygen i ka hana bactericidal o neutrophils, kahi mea nui o ka pane ʻana o ka pale. Eia kekahi, hoʻopau ʻo HBOT i ka neutrophil adhesion, i hoʻopili ʻia e ka launa pū ʻana o nā β-integrins ma nā neutrophils me nā molekole adhesion intercellular (ICAM) ma nā cell endothelial. Hoʻopaʻa ʻo HBOT i ka hana o ka neutrophil β-2 integrin (Mac-1, CD11b / CD18) ma o ka nitric oxide (NO)-mediated kaʻina, e hāʻawi ana i ka neʻe ʻana o nā neutrophils i kahi o ka maʻi.
Pono ka hoʻonohonoho hou ʻana o ka cytoskeleton no nā neutrophils e phagocytize pono i nā pathogens. Ua hōʻike ʻia ka S-nitrosylation o ka actin e hoʻoulu i ka polymerization actin, hiki ke hoʻomaʻamaʻa i ka hana phagocytic o neutrophils ma hope o ka HBOT pre-treatment. Eia kekahi, hoʻolaha ʻo HBOT i ka apoptosis i nā laina kelepona T kanaka ma o nā ala mitochondrial, me ka hōʻike ʻia ʻana o ka lymphocyte make post-HBOT. ʻO ka pale ʻana i ka caspase-9-me ka ʻole o ka hopena i ka caspase-8-ua hōʻike i ka hopena immunomodulatory o HBOT.
ʻO nā hopena Synergistic o HBOT me nā Antimicrobial Agents
I nā noi lapaʻau, hoʻohana pinepine ʻia ʻo HBOT me nā lāʻau antibiotic e hakakā pono i nā maʻi. Hiki i ke kūlana hyperoxic i loaʻa i ka wā HBOT ke hoʻololi i ka pono o kekahi mau lāʻau antibiotic. Hōʻike ka noiʻi i nā lāʻau bactericidal kikoʻī, e like me β-lactams, fluoroquinolones, a me aminoglycosides, ʻaʻole hana wale ma o nā ʻano hana maoli akā hilinaʻi pū kekahi i ka metabolism aerobic o ka bacteria. No laila, ʻo ka loaʻa ʻana o ka oxygen a me nā hiʻohiʻona metabolic o nā pathogens he pivotal i ka wā e loiloi ai i nā hopena therapeutic o nā antibiotics.
Ua hōʻike ʻia nā hōʻike koʻikoʻi e hiki i nā pae oxygen haʻahaʻa ke hoʻonui i ke kū'ē ʻana o Pseudomonas aeruginosa i ka piperacillin/tazobactam a ʻo ka haʻahaʻa oxygen haʻahaʻa e kōkua pū i ka piʻi ʻana o Enterobacter cloacae i ka azithromycin. ʻO ka mea ʻē aʻe, hiki i kekahi mau kūlana hypoxic ke hoʻonui i ka naʻau bacteria i nā antibiotic tetracycline. Hana ʻo HBOT ma ke ʻano he ala lapaʻau adjunctive kūpono ma o ka hoʻoulu ʻana i ka metabolism aerobic a me ka reoxygenating hypoxic infected tissues, a laila hoʻonui i ka naʻau o nā pathogens i nā lāʻau antibiotic.
I loko o nā haʻawina preclinical, ʻo ka hui pū ʻana o HBOT—hoʻohana ʻia ʻelua manawa i kēlā me kēia lā no 8 mau hola ma 280 kPa—me ka tobramycin (20 mg/kg/lā) i hoʻemi nui i nā ukana bacteria ma Staphylococcus aureus infectious endocarditis. Hōʻike kēia i ka hiki o HBOT ma ke ʻano he lapaʻau kōkua. Ua hōʻike ʻia nā noiʻi hou aʻe ma lalo o 37 ° C a me 3 ATA kaomi no 5 mau hola, ua hoʻonui nui ʻo HBOT i nā hopena o ka imipenem e kūʻē i ka macrophage-infected Pseudomonas aeruginosa. Hoʻohui ʻia, ʻoi aku ka maikaʻi o ka hoʻohui ʻana o ka HBOT me ka cephazolin i ka mālama ʻana i Staphylococcus aureus osteomyelitis i nā ʻano holoholona i hoʻohālikelike ʻia me cephazolin wale nō.
Hoʻonui nui ka HBOT i ka hana bactericidal o ciprofloxacin e kūʻē i nā biofilm Pseudomonas aeruginosa, ʻoi aku ma hope o 90 mau minuke o ka hoʻolaha ʻana. Hāʻawi ʻia kēia hoʻonui ʻana i ka hoʻokumu ʻana o nā ʻano oxygen reactive endogenous (ROS) a hōʻike i ka ʻike kiʻekiʻe i nā mutants peroxidase-defective.
I loko o nā hiʻohiʻona o ka pleuritis i hoʻokumu ʻia e ka methicillin-resistant Staphylococcus aureus (MRSA), ua hōʻike ʻia ka hopena hui pū o vancomycin, teicoplanin, a me linezolid me HBOT i ka hoʻonui nui ʻana i ka pono e kū'ē i ka MRSA. ʻO Metronidazole, he lāʻau lāʻau i hoʻohana nui ʻia i ka mālama ʻana i nā maʻi anaerobic a me nā maʻi polymicrobial koʻikoʻi e like me nā maʻi wāwae diabetic (DFIs) a me nā maʻi maʻi kahua ʻokiʻoki (SSIs), ua hōʻike ʻoi aku ka maikaʻi o ka antimicrobial ma lalo o nā kūlana anaerobic. Pono nā haʻawina e hiki mai ana e ʻimi i nā hopena antibacterial synergistic o HBOT i hui pū ʻia me metronidazole i loko o ka vivo a me ka hoʻonohonoho in vitro.
ʻO ka maikaʻi o ka antimicrobial o HBOT ma luna o nā bacteria pale
Me ka ulu ʻana a me ka hoʻolaha ʻana o nā maʻi kūʻē, nalowale nā antibiotic kuʻuna i ko lākou ikaika i ka wā. Eia kekahi, hiki i ka HBOT ke hōʻoia i ka mea nui i ka mālama ʻana a me ka pale ʻana i nā maʻi i hoʻokumu ʻia e nā pathogens multidrug-resistant, e lawelawe ana ma ke ʻano he hoʻolālā koʻikoʻi ke hāʻule nā lāʻau antibiotic. Ua hōʻike ʻia nā haʻawina he nui i nā hopena bactericidal koʻikoʻi o ka HBOT ma nā maʻi bacteria kūʻokoʻa pili i ke kino. No ka laʻana, he 90 mau minuke HBOT ma 2 ATM i hōʻemi nui i ka ulu ʻana o MRSA. Eia kekahi, ma nā ʻano hoʻohālike, ua hoʻonui ʻo HBOT i nā hopena antibacterial o nā lāʻau ʻokoʻa e kūʻē i nā maʻi MRSA. Ua hōʻoia ʻia nā hōʻike he kūpono ka HBOT i ka mālama ʻana i ka osteomyelitis i hoʻokumu ʻia e OXA-48-producing Klebsiella pneumoniae me ka ʻole o ke koi ʻana i nā lāʻau ʻokoʻa.
I ka hōʻuluʻulu ʻana, ʻo ka hyperbaric oxygen therapy e hōʻike ana i kahi ala multifaceted i ka mālama ʻana i ka maʻi, hoʻonui i ka pane ʻana i ka pale ʻana me ka hoʻonui ʻana i ka pono o nā mea antimicrobial i kēia manawa. Me ka noiʻi piha a me ka hoʻomohala ʻana, paʻa ia i ka hiki ke hoʻēmi i nā hopena o ka pale ʻana i ka antibiotic, e hāʻawi ana i ka manaʻolana i ka hoʻomau ʻana i ke kaua kūʻē i nā maʻi bacterial.
Ka manawa hoʻouna: Feb-28-2025